VistaGen Therapeutics Inc (VTGN)

[Johnny_C]

Ron, not giving you advice on what to do with your stock, but the fact is my math indicates that at most completely diluted we are looking at about 40 million shares.

In talking with the company, based on the cash portion of the Allegan Naurex buyout would be about $15.00 a share. Add to that over $25.00 on the backend through milestones. AGN seems to be progressing with the intravenous application in Phase 3.

The interesting thing about the 40 million shares is that basing the structure on all the financing being done down at these levels.

Just my opinion, but I doubt that will happen. There are some events like fast track, more patents, the NIH results, the beginning of Phase 2 injunctive that could clean up the shares.

If they get an oral blockbuster through phase 2 how many multiples do you think that drug would be worth compared to an intravenous application that you make an appointment with a doctor, sit in a waiting room, then sit getting the drug and then sit for an hour before being released.

Biotechs carry risk, but a tremendous amount of upside.

There is also the stem cell division